Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.

[1]  R. Burger,et al.  Use of a dummy (pacifier) during sleep and risk of sudden infant death syndrome (SIDS): population based case-control study , 2005, BMJ : British Medical Journal.

[2]  L. Harrison,et al.  Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma , 2005, Journal of surgical oncology.

[3]  E. Eisenhauer,et al.  Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). , 2005, Journal of the National Cancer Institute.

[4]  I. Chiappino,et al.  Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Recurrent Peritoneal Carcinomatosis from Ovarian Cancer , 2004, World Journal of Surgery.

[5]  J. H. Kim,et al.  Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. , 2004, Gynecologic oncology.

[6]  J. Gori,et al.  Intraperitoneal hyperthermic chemotherapy in ovarian cancer , 2004, International Journal of Gynecologic Cancer.

[7]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Sugarbaker,et al.  Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum , 2003, International Journal of Gynecologic Cancer.

[9]  D. Tsiftsis,et al.  Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. , 2003, Anticancer research.

[10]  H. Ajisaka,et al.  Long-term survival of a patient with primary papillary serous carcinoma of the peritoneum treated by subtotal peritonectomy plus intraoperative chemohyperthermia. , 2002, Hepato-gastroenterology.

[11]  F. Bressolle,et al.  Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. , 2002, Anticancer research.

[12]  K. Geisinger,et al.  Prospective Trial for the Treatment of Malignant Peritoneal Mesothelioma , 2001, The American surgeon.

[13]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  N. Santoro,et al.  Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study , 2001, Tumori.

[15]  F. van Coevorden,et al.  Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. , 2001, European journal of cancer.

[16]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Beijnen,et al.  Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  M. Parmar,et al.  Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. , 2000, Journal of the National Cancer Institute.

[19]  D. Giannarelli,et al.  Treatment of peritoneal carcinomatosis with intent to cure , 2000, Journal of surgical oncology.

[20]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[21]  P. Sugarbaker.  Management of peritoneal-surface malignancy: the surgeon’s role , 1999, Langenbeck's Archives of Surgery.

[22]  P. Sugarbaker,et al.  Results of Treatment of 385 Patients With Peritoneal Surface Spread of Appendiceal Malignancy , 1999, Annals of Surgical Oncology.

[23]  S. Libutti,et al.  A Phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis , 1998, Cancer.

[24]  S. Fujimoto,et al.  Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery , 1997, Cancer.

[25]  D. Alberts,et al.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.

[26]  E. Partridge,et al.  Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). , 1996, Seminars in oncology.

[27]  P. Sugarbaker,et al.  Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy , 1996, Cancer.

[28]  K. Ono,et al.  Effect of hyperthermia on the number of platinum atoms binding to DNA of HeLa cells treated with 195mPt-radiolabelled cis-diaminedichloroplatinum(II). , 1994, International journal of radiation biology.

[29]  H. Pinedo,et al.  Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. , 1994, British Journal of Cancer.

[30]  D. Alberts,et al.  Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  W. Cunliffe,et al.  Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. , 1990, Cancer research.

[32]  M. Kaufmann,et al.  Effect of hyperthermia on cis-diamminedichloroplatinum(II) (rhodamine 123)2[tetrachloroplatinum(II)] in a human squamous cell carcinoma line and a cis-diamminedichloroplatinum(II)-resistant subline. , 1988, Cancer research.

[33]  D. Alberts,et al.  Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. , 1980, Journal of the National Cancer Institute.

[34]  R. Meyn,et al.  Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). , 1980, Cancer research.

[35]  G. Hahn.  Potential for therapy of drugs and hyperthermia. , 1979, Cancer research.

[36]  B. Giovanella,et al.  Selective lethal effect of supranormal temperatures on human neoplastic cells. , 1976, Cancer research.

[37]  F M Muggia,et al.  Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  E. Trimble,et al.  A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer , 1999, Cancer Chemotherapy and Pharmacology.

[39]  E. Trimble,et al.  Erratum: A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer (Cancer Chemotherapy and Pharmacology (1999) 43 (106-114)) , 1999 .

[40]  H. Bartelink,et al.  Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. , 1998, European journal of cancer.

[41]  B. Loggie,et al.  Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers , 1994 .